EcoDrugPlus

Notch Receptor 3

Ensembl ID : ENSMMDG00005023344
Gene Symbol: NOTCH3
1 Cross references
199 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSMMDG00005018695
Gene Symbol: NFKB1
1 Cross references
200 Possible Orthologues:

Nuclear Factor, Erythroid 2 Like 2

Ensembl ID : ENSMMDG00005018097
Gene Symbol: NFE2L2
3 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSMMDG00005022693
Gene Symbol: NR1H3
3 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSMMDG00005016699
Gene Symbol: NR1H4
3 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSMMDG00005008492
Gene Symbol: NR3C1
3 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSMMDG00005007914
Gene Symbol: NR3C2
3 Cross references
211 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSMMDG00005021064
Gene Symbol: NOD2
1 Cross references
166 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSMMDG00005022641
Gene Symbol: OPRK1
3 Cross references
197 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSMMDG00005015052
Gene Symbol: OPRD1B
1 Cross references
179 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSMMDG00005004715
Gene Symbol: OXTR
3 Cross references
183 Possible Orthologues:

Oxytocin Receptor A

Ensembl ID : ENSMMDG00005005349
Gene Symbol: OXTRA
1 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).